{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:16:15Z","timestamp":1790090175857,"version":"4.0.1"},"reference-count":188,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Probiotics & Antimicro. Prot."],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12602-026-11014-w","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T02:56:17Z","timestamp":1776221777000},"page":"9097-9121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Gut-Brain Axis: A Critical Link between Type 2 Diabetes and Parkinson\u2019s disease"],"prefix":"10.1007","volume":"18","author":[{"given":"Najlaa Hamed","family":"Almohmadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder M.","family":"Al-kuraishy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khulood S.","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arwa M.","family":"Turkistani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatimah M.","family":"Yousef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali I.","family":"Al-Gareeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaser Hosny Ali","family":"Elewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaber El-Saber","family":"Batiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"11014_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2018.00013","volume":"8","author":"J Gao","year":"2018","unstructured":"Gao J, Xu K, Liu H, Liu G, Bai M, Peng C, Li T, Yin Y (2018) Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. Front Cell Infect Microbiol 8:13. https:\/\/doi.org\/10.3389\/fcimb.2018.00013","journal-title":"Front Cell Infect Microbiol"},{"key":"11014_CR2","doi-asserted-by":"publisher","first-page":"206","DOI":"10.4183\/aeb.2016.206","volume":"12","author":"I Grigorescu","year":"2016","unstructured":"Grigorescu I, Dumitrascu DL (2016) Implication of gut microbiota in diabetes mellitus and obesity. Acta Endocrinol (Copenh) 12:206\u2013214. https:\/\/doi.org\/10.4183\/aeb.2016.206","journal-title":"Acta Endocrinol (Copenh)"},{"key":"11014_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-025-56829-3","volume":"16","author":"S Romano","year":"2025","unstructured":"Romano S, Wirbel J, Ansorge R, Schudoma C, Ducarmon QR, Narbad A, Zeller G (2025) Machine learning-based meta-analysis reveals gut microbiome alterations associated with Parkinson\u2019s disease. Nat Commun 16:4227. https:\/\/doi.org\/10.1038\/S41467-025-56829-3","journal-title":"Nat Commun"},{"key":"11014_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-023-40874-X","author":"G Ecklu-Mensah","year":"2023","unstructured":"Ecklu-Mensah G, Choo-Kang C, Maseng MG, Donato S, Bovet P, Viswanathan B, Bedu-Addo K, Plange-Rhule J, Oti Boateng P, Forrester TE, Williams M, Lambert EV, Rae D, Sinyanya N, Luke A, Layden BT, O\u2019Keefe S, Gilbert JA, Dugas LR (2023) Gut microbiota and fecal short chain fatty acids differ with adiposity and country of origin: the METS-microbiome study. Nat Commun. https:\/\/doi.org\/10.1038\/S41467-023-40874-X","journal-title":"Nat Commun"},{"key":"11014_CR5","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/nrneurol.2015.197","volume":"11","author":"L Klingelhoefer","year":"2015","unstructured":"Klingelhoefer L, Reichmann H (2015) Pathogenesis of Parkinson disease - the gut-brain axis and environmental factors. Nat Rev Neurol 11:625\u2013636. https:\/\/doi.org\/10.1038\/nrneurol.2015.197","journal-title":"Nat Rev Neurol"},{"key":"11014_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2017.00441","volume":"9","author":"X Yang","year":"2018","unstructured":"Yang X, Qian Y, Xu S, Song Y, Xiao Q (2018) Longitudinal analysis of fecal microbiome and pathologic processes in a rotenone induced mice model of Parkinson\u2019s disease. Front Aging Neurosci 9:441. https:\/\/doi.org\/10.3389\/fnagi.2017.00441","journal-title":"Front Aging Neurosci"},{"key":"11014_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ejphar.2017.05.042","volume":"817","author":"P Perez-Pardo","year":"2017","unstructured":"Perez-Pardo P, Kliest T, Dodiya HB, Broersen LM, Garssen J, Keshavarzian A, Kraneveld AD (2017) The gut-brain axis in Parkinson\u2019s disease: possibilities for food-based therapies. Eur J Pharmacol 817:86\u201395. https:\/\/doi.org\/10.1016\/j.ejphar.2017.05.042","journal-title":"Eur J Pharmacol"},{"key":"11014_CR8","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/ene.13919","volume":"26","author":"R Durcan","year":"2019","unstructured":"Durcan R, Wiblin L, Lawson RA, Khoo TK, Yarnall AJ, Duncan GW, Brooks DJ, Pavese N, Burn DJ (2019) Prevalence and duration of non-motor symptoms in prodromal Parkinson\u2019s disease. Eur J Neurol 26:979\u2013985. https:\/\/doi.org\/10.1111\/ene.13919","journal-title":"Eur J Neurol"},{"key":"11014_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2025.156983","volume":"193","author":"SM Alshahrani","year":"2025","unstructured":"Alshahrani SM, Al-Kuraishy HM, Albuhadily AK, Al-Gareeb AI, Abdelaziz AM, Alexiou A, Papadakis M, Alruwaili M, Batiha GES (2025) GDF15 upregulation in Parkinson\u2019s disease: compensatory mechanisms and causal insights. Cytokine 193:156983. https:\/\/doi.org\/10.1016\/j.cyto.2025.156983","journal-title":"Cytokine"},{"key":"11014_CR10","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1037\/neu0000544","volume":"33","author":"B Leonhardt","year":"2019","unstructured":"Leonhardt B, Tahmasebi R, Jagsch R, Pirker W, Lehrner J (2019) Awareness of olfactory dysfunction in parkinsons disease. Neuropsychology 33:633\u2013641. https:\/\/doi.org\/10.1037\/neu0000544","journal-title":"Neuropsychology"},{"key":"11014_CR11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1136\/gutjnl-2014-308778","volume":"65","author":"MC Dao","year":"2016","unstructured":"Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, Kayser BD, Levenez F, Chilloux J, Hoyles L, Dumas ME, Rizkalla SW, Dor\u00e9 J, Cani PD, Cl\u00e9ment K, Le Mouha\u00ebr S, Cotillard A, Kennedy SP, Pons N, Le Chatelier E, Almeida M, Quinquis B, Galleron N, Batto JM, Renault P, Zucker JD, Ehrlich SD, Blotti\u00e8re H, Leclerc M, Juste C, De Wouters T, Lepage P (2016) Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut 65:426\u2013436. https:\/\/doi.org\/10.1136\/gutjnl-2014-308778","journal-title":"Gut"},{"key":"11014_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/microorganisms8101587","volume":"8","author":"JY Yoo","year":"2020","unstructured":"Yoo JY, Groer M, Dutra SVO, Sarkar A, McSkimming DI (2020) Gut microbiota and immune system interactions. Microorganisms 8:1\u201322. https:\/\/doi.org\/10.3390\/microorganisms8101587","journal-title":"Microorganisms"},{"key":"11014_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01830","volume":"9","author":"V Lazar","year":"2018","unstructured":"Lazar V, Ditu LM, Pircalabioru GG, Gheorghe I, Curutiu C, Holban AM, Picu A, Petcu L, Chifiriuc MC (2018) Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer. Front Immunol 9:1830. https:\/\/doi.org\/10.3389\/fimmu.2018.01830","journal-title":"Front Immunol"},{"key":"11014_CR14","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1096\/fj.201600832R","volume":"31","author":"S Dagdeviren","year":"2017","unstructured":"Dagdeviren S, Jung DY, Friedline RH, Noh HL, Kim JH, Patel PR, Tsitsilianos N, Inashima K, Tran DA, Hu X, Loubato MM, Craige SM, Kwon JY, Lee KW, Kim JK (2017) IL-10 prevents aging-associated inflammation and insulin resistance in skeletal muscle. FASEB J 31:701\u2013710. https:\/\/doi.org\/10.1096\/fj.201600832R","journal-title":"FASEB J"},{"key":"11014_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature13564","volume":"514","author":"X Wang","year":"2014","unstructured":"Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eidenschenk C, Zhang J, Lesch J, Lee WP, Ross J, Diehl L, Van Bruggen N, Kolumam G, Ouyang W (2014) Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature 514:237\u2013241. https:\/\/doi.org\/10.1038\/nature13564","journal-title":"Nature"},{"key":"11014_CR16","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1039\/c6fo00831c","volume":"7","author":"P Tian","year":"2016","unstructured":"Tian P, Li B, He C, Song W, Hou A, Tian S, Meng X, Li K, Shan Y (2016) Antidiabetic (type 2) effects of Lactobacillus G15 and Q14 in rats through regulation of intestinal permeability and microbiota. Food Funct 7:3789\u20133797. https:\/\/doi.org\/10.1039\/c6fo00831c","journal-title":"Food Funct"},{"key":"11014_CR17","doi-asserted-by":"publisher","unstructured":"Breyner NM, Michon C, de Sousa CS, Vilas Boas PB, Chain F, Azevedo VA, Langella P, Chatel JM (2017) Microbial anti-inflammatory molecule (MAM) from Faecalibacterium prausnitzii shows a protective effect on DNBS and DSS-induced colitis model in mice through inhibition of NF-\u03baB pathway. Front Microbiol 8. https:\/\/doi.org\/10.3389\/fmicb.2017.00114","DOI":"10.3389\/fmicb.2017.00114"},{"key":"11014_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4103\/japtr.JAPTR_65_19","volume":"10","author":"H Rasheed","year":"2019","unstructured":"Rasheed H, Al-Kuraishy H, Al-Gareeb A, Hussien N, Al-Nami M (2019) Effects of diabetic pharmacotherapy on prolactin hormone in patients with type 2 diabetes mellitus: Bane or Boon. J Adv Pharm Technol Res 10:163\u2013168. https:\/\/doi.org\/10.4103\/japtr.JAPTR_65_19","journal-title":"J Adv Pharm Technol Res"},{"key":"11014_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177593","author":"M Alanazi","year":"2025","unstructured":"Alanazi M, Al-Kuraishy HM, Albuhadily AK, Al-Gareeb AI, Abdelaziz AM, Alexiou A, Papadakis M, Batiha GES (2025) The protective effect of amylin in type 2 diabetes: yes or no. Eur J Pharmacol. https:\/\/doi.org\/10.1016\/j.ejphar.2025.177593","journal-title":"Eur J Pharmacol"},{"key":"11014_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.644295","volume":"8","author":"HM Al-kuraishy","year":"2021","unstructured":"Al-kuraishy HM, Al-Gareeb AI, Alblihed M, Cruz-Martins N, Batiha GES (2021) COVID-19 and risk of acute ischemic stroke and acute lung injury in patients with type II diabetes mellitus: the anti-inflammatory role of metformin. Front Med 8:644295. https:\/\/doi.org\/10.3389\/fmed.2021.644295","journal-title":"Front Med"},{"key":"11014_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.4103\/japtr.JAPTR_18_20","volume":"11","author":"H Al-Kuraishy","year":"2020","unstructured":"Al-Kuraishy H, Sami O, Hussain N, Al-Gareeb A (2020) Metformin and\/or vildagliptin mitigate type II diabetes mellitus induced-oxidative stress: the intriguing effect. J Adv Pharm Technol Res 11:142\u2013147. https:\/\/doi.org\/10.4103\/japtr.JAPTR_18_20","journal-title":"J Adv Pharm Technol Res"},{"key":"11014_CR22","doi-asserted-by":"publisher","first-page":"166","DOI":"10.4103\/bbrj.bbrj_7_20","volume":"4","author":"MH Abdul-Hadi","year":"2020","unstructured":"Abdul-Hadi MH, Naji MT, Shams HA, Sami OM, Al-Harchan NAA, Al-Kuraishy HM, Al-Gareeb AI (2020) Oxidative stress injury and glucolipotoxicity in type 2 diabetes mellitus: the potential role of metformin and sitagliptin. Biomed Biotechnol Res J 4:166\u2013172. https:\/\/doi.org\/10.4103\/bbrj.bbrj_7_20","journal-title":"Biomed Biotechnol Res J"},{"key":"11014_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.4103\/ijciis.ijciis_40_19","volume":"9","author":"M Al-Nami","year":"2019","unstructured":"Al-Nami M, Al-Kuraishy H, Al-Gareeb A, Al-Mamoori F (2019) Metabolic profile and prolactin serum levels in men with type 2 diabetes mellitus: old-new rubric. Int J Crit Illn Inj Sci 9:120. https:\/\/doi.org\/10.4103\/ijciis.ijciis_40_19","journal-title":"Int J Crit Illn Inj Sci"},{"key":"11014_CR24","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/jam.12573","volume":"117","author":"SH Kim","year":"2014","unstructured":"Kim SH, Huh CS, Choi ID, Jeong JW, Ku HK, Ra JH, Kim TY, Kim GB, Sim JH, Ahn YT (2014) The anti-diabetic activity of Bifidobacterium lactis HY8101 in vitro and in vivo. J Appl Microbiol 117:834\u2013845. https:\/\/doi.org\/10.1111\/jam.12573","journal-title":"J Appl Microbiol"},{"key":"11014_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054617","volume":"8","author":"JH Kang","year":"2013","unstructured":"Kang JH, Yun SI, Park MH, Park JH, Jeong SY, Park HO (2013) Anti-obesity effect of lactobacillus gasseri bnr17 in high-sucrose diet-induced obese mice. PLoS One 8:e54617. https:\/\/doi.org\/10.1371\/journal.pone.0054617","journal-title":"PLoS One"},{"key":"11014_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7498","volume":"6","author":"J Miao","year":"2015","unstructured":"Miao J, Ling AV, Manthena PV, Gearing ME, Graham MJ, Crooke RM, Croce KJ, Esquejo RM, Clish CB, Torrecilla E, V\u00e1zquez GF, Rubio MA, Cabrerizo L, Barabash A, Pernaute AS, Torres AJ, Vicent D, Biddinger SB (2015) Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis. Nat Commun 6:6498. https:\/\/doi.org\/10.1038\/ncomms7498","journal-title":"Nat Commun"},{"key":"11014_CR27","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3920\/BM2016.0167","volume":"8","author":"X Li","year":"2017","unstructured":"Li X, Wang E, Yin B, Fang D, Chen P, Wang G, Zhao J, Zhang H, Chen W (2017) Effects of lactobacillus casei CCFM419 on insulin resistance and gut microbiota in type 2 diabetic mice. Beneficial Microbes 8:421\u2013432. https:\/\/doi.org\/10.3920\/BM2016.0167","journal-title":"Beneficial Microbes"},{"key":"11014_CR28","doi-asserted-by":"publisher","first-page":"R167","DOI":"10.1530\/EJE-14-0874","volume":"172","author":"KH Allin","year":"2015","unstructured":"Allin KH, Nielsen T, Pedersen O (2015) Mechanisms in endocrinology: gut microbiota in patients with type 2 diabetes mellitus. Eur J Endocrinol 172:R167\u2013R177. https:\/\/doi.org\/10.1530\/EJE-14-0874","journal-title":"Eur J Endocrinol"},{"key":"11014_CR29","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/NATURE15766","volume":"528","author":"K Forslund","year":"2015","unstructured":"Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, Prifti E, Vieira-Silva S, Gudmundsdottir V, Pedersen HK, Arumugam M, Kristiansen K, Voigt AY, Vestergaard H, Hercog R, Costea PI, Kultima JR, Li J, J\u00f8rgensen T, Levenez F, Dore J, Nielsen HB, Brunak S, Raes J, Hansen T, Wang J, Ehrlich SD, Bork P, Pedersen O (2015) Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528:262\u2013266. https:\/\/doi.org\/10.1038\/NATURE15766","journal-title":"Nature"},{"key":"11014_CR30","doi-asserted-by":"publisher","unstructured":"Geurts L, Lazarevic V, Derrien M, Everard A, Van Roye M, Knauf C, Valet P, Girard M, Muccioli GG, Fran\u00e7ois P, de Vos WM, Schrenzel J, Delzenne NM, Cani PD (2011) Altered gut microbiota and endocannabinoid system tone in obese and diabetic leptin-resistant mice: impact on apelin regulation in adipose tissue. Front Microbiol 2. https:\/\/doi.org\/10.3389\/FMICB.2011.00149","DOI":"10.3389\/FMICB.2011.00149"},{"key":"11014_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41195-0","volume":"9","author":"IN Kieler","year":"2019","unstructured":"Kieler IN, Osto M, Hugentobler L, Puetz L, Gilbert MTP, Hansen T, Pedersen O, Reusch CE, Zini E, Lutz TA, Bj\u00f8rnvad CR (2019) Diabetic cats have decreased gut microbial diversity and a lack of butyrate producing bacteria. Sci Rep 9:4822. https:\/\/doi.org\/10.1038\/s41598-019-41195-0","journal-title":"Sci Rep"},{"key":"11014_CR32","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1264\/jsme2.ME14054","volume":"29","author":"K Kameyama","year":"2014","unstructured":"Kameyama K, Itoh K (2014) Intestinal colonization by a lachnospiraceae bacterium contributes to the development of diabetes in obese mice. Microbes Environ 29:427\u2013430. https:\/\/doi.org\/10.1264\/jsme2.ME14054","journal-title":"Microbes Environ"},{"key":"11014_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009085","author":"N Larsen","year":"2010","unstructured":"Larsen N, Vogensen FK, Van Den Berg FWJ, Nielsen DS, Andreasen AS, Pedersen BK, Al-Soud WA, S\u00f8rensen SJ, Hansen LH, Jakobsen M (2010) Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0009085","journal-title":"PLoS ONE"},{"key":"11014_CR34","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.37358\/rc.18.8.6512","volume":"69","author":"AI Suceveanu","year":"2018","unstructured":"Suceveanu AI, Stoian AP, Parepa I, Voinea C, Hainarosie R, Manuc D, Nitipir C, Mazilu L, Suceveanu AP (2018) Gut microbiota patterns in obese and type 2 diabetes (T2D) patients from romanian black sea coast region. Rev Chim 69:2260\u20132267. https:\/\/doi.org\/10.37358\/rc.18.8.6512","journal-title":"Rev Chim"},{"key":"11014_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2017.00602","volume":"8","author":"JX Song","year":"2017","unstructured":"Song JX, Ren H, Gao YF, Lee CY, Li SF, Zhang F, Li L, Chen H (2017) Dietary capsaicin improves glucose homeostasis and alters the gut microbiota in obese diabetic ob\/ob mice. Front Physiol 8:602. https:\/\/doi.org\/10.3389\/fphys.2017.00602","journal-title":"Front Physiol"},{"key":"11014_CR36","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1039\/c9fo00475k","volume":"10","author":"R Hu","year":"2019","unstructured":"Hu R, Zeng F, Wu L, Wan X, Chen Y, Zhang J, Liu B (2019) Fermented carrot juice attenuates type 2 diabetes by mediating gut microbiota in rats. Food Funct 10:2935\u20132946. https:\/\/doi.org\/10.1039\/c9fo00475k","journal-title":"Food Funct"},{"key":"11014_CR37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jdiacomp.2010.03.003","volume":"25","author":"VS Thorve","year":"2011","unstructured":"Thorve VS, Kshirsagar AD, Vyawahare NS, Joshi VS, Ingale KG, Mohite RJ (2011) Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management. J Diabetes Complications 25:129\u2013136. https:\/\/doi.org\/10.1016\/j.jdiacomp.2010.03.003","journal-title":"J Diabetes Complications"},{"key":"11014_CR38","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11596-017-1767-z","volume":"37","author":"H Li","year":"2017","unstructured":"Li H, Qi T, Huang Z, Ying Y, Zhang Y, Wang B, Ye L, Zhang B, Chen D, Chen J (2017) Relationship between gut microbiota and type 2 diabetic erectile dysfunction in Sprague-Dawley rats. J Huazhong Univ Sci Technol [Med Sci] 37:523\u2013530. https:\/\/doi.org\/10.1007\/s11596-017-1767-z","journal-title":"J Huazhong Univ Sci Technol [Med Sci]"},{"key":"11014_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109138","volume":"117","author":"Q Ma","year":"2019","unstructured":"Ma Q, Li Y, Li P, Wang M, Wang J, Tang Z, Wang T, Luo L, Wang C, Zhao B (2019) Research progress in the relationship between type 2 diabetes mellitus and intestinal flora. Biomed Pharmacother 117:109138. https:\/\/doi.org\/10.1016\/j.biopha.2019.109138","journal-title":"Biomed Pharmacother"},{"key":"11014_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119311","volume":"273","author":"A Arora","year":"2021","unstructured":"Arora A, Behl T, Sehgal A, Singh S, Sharma N, Bhatia S, Sobarzo-Sanchez E, Bungau S (2021) Unravelling the involvement of gut microbiota in type 2 diabetes mellitus. Life Sci 273:119311. https:\/\/doi.org\/10.1016\/j.lfs.2021.119311","journal-title":"Life Sci"},{"key":"11014_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE (2017) Parkinson disease. Nat Rev Dis Primers 3:1\u201321. https:\/\/doi.org\/10.1038\/nrdp.2017.13","journal-title":"Nat Rev Dis Primers"},{"key":"11014_CR42","doi-asserted-by":"publisher","unstructured":"Abdelaziz AM, Rasheed NOA, Zaki HF, Salem HA, El-Sayed RM (2024) Canagliflozin attenuates neurodegeneration and ameliorates dyskinesia through targeting the NLRP3\/Nurr1\/GSK-3\u03b2\/SIRT3 pathway and autophagy modulation in rotenone-lesioned rats. Int Immunopharmacol 146. https:\/\/doi.org\/10.1016\/J.INTIMP.2024.113839","DOI":"10.1016\/J.INTIMP.2024.113839"},{"key":"11014_CR43","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1001\/jamaneurol.2016.0947","volume":"73","author":"R Savica","year":"2016","unstructured":"Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA (2016) Time trends in the incidence of parkinson disease. JAMA Neurol 73:981\u2013989. https:\/\/doi.org\/10.1001\/jamaneurol.2016.0947","journal-title":"JAMA Neurol"},{"key":"11014_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/J.BRAINRESBULL.2025.111349","volume":"225","author":"NH Almohmadi","year":"2025","unstructured":"Almohmadi NH, Al-kuraishy HM, Al-Gareeb AI, Albuhadily AK, Abdelaziz AM, Jabir MS, Alexiou A, Papadakis M, Batiha GES (2025) Glutamatergic dysfunction in neurodegenerative diseases focusing on Parkinson\u2019s disease: role of glutamate modulators. Brain Res Bull 225:111349. https:\/\/doi.org\/10.1016\/J.BRAINRESBULL.2025.111349","journal-title":"Brain Res Bull"},{"key":"11014_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/J.INTIMP.2023.109986","volume":"117","author":"RM El-Sayed","year":"2023","unstructured":"El-Sayed RM, Abdelaziz AM, Zaki HF, Abdel Rasheed NO (2023) Cilostazol novel neuroprotective mechanism against rotenone-induced Parkinson\u2019s disease in rats: correlation between Nrf2 and HMGB1\/TLR4\/PI3K\/Akt\/mTOR signaling. Int Immunopharmacol 117:109986. https:\/\/doi.org\/10.1016\/J.INTIMP.2023.109986","journal-title":"Int Immunopharmacol"},{"key":"11014_CR46","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.parkreldis.2017.07.033","volume":"46","author":"DW Dickson","year":"2018","unstructured":"Dickson DW (2018) Neuropathology of Parkinson disease. Parkinsonism Relat Disord 46:S30\u2013S33. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.07.033","journal-title":"Parkinsonism Relat Disord"},{"key":"11014_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/J.INTIMP.2025.114692","volume":"156","author":"AM Abdelaziz","year":"2025","unstructured":"Abdelaziz AM (2025) Alpha-Synuclein drives NURR1 and NLRP3 inflammasome dysregulation in Parkinson\u2019s disease: from pathogenesis to potential therapeutic strategies. Int Immunopharmacol 156:114692. https:\/\/doi.org\/10.1016\/J.INTIMP.2025.114692","journal-title":"Int Immunopharmacol"},{"key":"11014_CR48","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1074\/jbc.RA118.004471","volume":"294","author":"TR Yamasaki","year":"2019","unstructured":"Yamasaki TR, Holmes BB, Furman JL, Dhavale DD, Su BW, Song ES, Cairns NJ, Kotzbauer PT, Diamond MI (2019) Parkinson\u2019s disease and multiple system atrophy have distinct \u03b1-synuclein seed characteristics. J Biol Chem 294:1045\u20131058. https:\/\/doi.org\/10.1074\/jbc.RA118.004471","journal-title":"J Biol Chem"},{"key":"11014_CR49","doi-asserted-by":"publisher","unstructured":"Tunold JA, Geut H, Rozemuller JMA, Henriksen SP, Toft M, van de Berg WDJ, Pihlstr\u00f8m L (2021) APOE and MAPT are associated with dementia in neuropathologically confirmed Parkinson\u2019s Disease. Front Neurol 12. https:\/\/doi.org\/10.3389\/FNEUR.2021.631145","DOI":"10.3389\/FNEUR.2021.631145"},{"key":"11014_CR50","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s10517-017-3700-7","volume":"162","author":"VA Petrov","year":"2017","unstructured":"Petrov VA, Saltykova IV, Zhukova IA, Alifirova VM, Zhukova NG, Dorofeeva YB, Tyakht AV, Kovarsky BA, Alekseev DG, Kostryukova ES, Mironova YS, Izhboldina OP, Nikitina MA, Perevozchikova TV, Fait EA, Babenko VV, Vakhitova MT, Govorun VM, Sazonov AE (2017) Analysis of gut microbiota in patients with Parkinson\u2019s disease. Bull Exp Biol Med 162:734\u2013737. https:\/\/doi.org\/10.1007\/s10517-017-3700-7","journal-title":"Bull Exp Biol Med"},{"key":"11014_CR51","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.neurol.2023.11.004","volume":"180","author":"B Bonaz","year":"2024","unstructured":"Bonaz B (2024) The gut-brain axis in Parkinson\u2019s disease. Rev Neurol (Paris) 180:65\u201378. https:\/\/doi.org\/10.1016\/j.neurol.2023.11.004","journal-title":"Rev Neurol (Paris)"},{"key":"11014_CR52","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/mds.26069","volume":"30","author":"F Scheperjans","year":"2015","unstructured":"Scheperjans F, Aho V, Pereira PAB, Koskinen K, Paulin L, Pekkonen E, Haapaniemi E, Kaakkola S, Eerola-Rautio J, Pohja M, Kinnunen E, Murros K, Auvinen P (2015) Gut microbiota are related to Parkinson\u2019s disease and clinical phenotype. Mov Disord 30:350\u2013358. https:\/\/doi.org\/10.1002\/mds.26069","journal-title":"Mov Disord"},{"key":"11014_CR53","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2174\/1570159x18666200606233050","volume":"19","author":"G Kaur","year":"2020","unstructured":"Kaur G, Behl T, Bungau S, Kumar A, Uddin MS, Mehta V, Zengin G, Mathew B, Shah MA, Arora S (2020) Dysregulation of the gut-brain axis, dysbiosis and influence of numerous factors on gut microbiota associated Parkinson\u2019s disease. Curr Neuropharmacol 19:233\u2013247. https:\/\/doi.org\/10.2174\/1570159x18666200606233050","journal-title":"Curr Neuropharmacol"},{"key":"11014_CR54","doi-asserted-by":"publisher","unstructured":"Wu H, Wei J, Zhao X, Liu Y, Chen Z, Wei K, Lu J, Chen W, Jiang M, Li S, Chen T (2023) Neuroprotective effects of an engineered Escherichia coli Nissle 1917 on Parkinson\u2019s disease in mice by delivering GLP-1 and modulating gut microbiota. Bioeng Transl Med 8. https:\/\/doi.org\/10.1002\/BTM2.10351","DOI":"10.1002\/BTM2.10351"},{"key":"11014_CR55","doi-asserted-by":"publisher","first-page":"7205","DOI":"10.3390\/ijms24087205","volume":"24","author":"M Chen","year":"2023","unstructured":"Chen M, Mor DE (2023) Gut-to-brain \u03b1-synuclein transmission in Parkinson\u2019s disease: evidence for prion-like mechanisms. Int J Mol Sci 24:7205. https:\/\/doi.org\/10.3390\/ijms24087205","journal-title":"Int J Mol Sci"},{"key":"11014_CR56","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1001\/ARCHNEUR.63.3.NOC50312","volume":"63","author":"LML De Lau","year":"2006","unstructured":"De Lau LML, Koudstaal PJ, Hofman A, Breteler MMB (2006) Subjective complaints precede Parkinson disease: the rotterdam study. Arch Neurol 63:362\u2013365. https:\/\/doi.org\/10.1001\/ARCHNEUR.63.3.NOC50312","journal-title":"Arch Neurol"},{"key":"11014_CR57","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/ANA.24448","volume":"78","author":"E Svensson","year":"2015","unstructured":"Svensson E, Horv\u00e1th-Puh\u00f3 E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, S\u00f8rensen HT (2015) Vagotomy and subsequent risk of Parkinson\u2019s disease. Ann Neurol 78:522\u2013529. https:\/\/doi.org\/10.1002\/ANA.24448","journal-title":"Ann Neurol"},{"key":"11014_CR58","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","volume":"103","author":"S Kim","year":"2019","unstructured":"Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, Lee JH, Kim WR, Kook M, Foss CA, Shen C, Lee H, Kulkarni S, Pasricha PJ, Lee G, Pomper MG, Dawson VL, Dawson TM, Ko HS (2019) Transneuronal propagation of pathologic \u03b1-synuclein from the gut to the brain models Parkinson\u2019s disease. Neuron 103:627-641.e7. https:\/\/doi.org\/10.1016\/j.neuron.2019.05.035","journal-title":"Neuron"},{"key":"11014_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0008762","volume":"5","author":"F Pan-Montojo","year":"2010","unstructured":"Pan-Montojo F, Anichtchik O, Dening Y, Knels L, Pursche S, Jung R, Jackson S, Gille G, Spillantini MG, Reichmann H, Funk RHW (2010) Progression of Parkinson\u2019s disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One 5:e8762. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0008762","journal-title":"PLoS One"},{"key":"11014_CR60","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.brainres.2017.04.019","volume":"1667","author":"F Hopfner","year":"2017","unstructured":"Hopfner F, K\u00fcnstner A, M\u00fcller SH, K\u00fcnzel S, Zeuner KE, Margraf NG, Deuschl G, Baines JF, Kuhlenb\u00e4umer G (2017) Gut microbiota in Parkinson disease in a Northern German Cohort. Brain Res 1667:41\u201345. https:\/\/doi.org\/10.1016\/j.brainres.2017.04.019","journal-title":"Brain Res"},{"key":"11014_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121356","author":"E Sheikhpour","year":"2023","unstructured":"Sheikhpour E, Mard SA, Farbood Y, Bavarsad K, Sarkaki A (2023) The effects of gallic acid and vagotomy on motor function, intestinal transit, brain electrophysiology and oxidative stress alterations in a rat model of Parkinson\u2019s disease induced by rotenone. Life Sci. https:\/\/doi.org\/10.1016\/j.lfs.2022.121356","journal-title":"Life Sci"},{"key":"11014_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/J.BRAINRES.2018.01.010","volume":"1693","author":"RA Liddle","year":"2018","unstructured":"Liddle RA (2018) Parkinson\u2019s disease from the gut. Brain Res 1693:201. https:\/\/doi.org\/10.1016\/J.BRAINRES.2018.01.010","journal-title":"Brain Res"},{"key":"11014_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.636545","volume":"13","author":"T Shen","year":"2021","unstructured":"Shen T, Yue Y, He T, Huang C, Qu B, Lv W, Lai HY (2021) The association between the gut microbiota and Parkinson\u2019s disease, a meta-analysis. Front Aging Neurosci 13:636545. https:\/\/doi.org\/10.3389\/fnagi.2021.636545","journal-title":"Front Aging Neurosci"},{"key":"11014_CR64","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.parkreldis.2016.08.019","volume":"32","author":"MM Unger","year":"2016","unstructured":"Unger MM, Spiegel J, Dillmann KU, Grundmann D, Philippeit H, B\u00fcrmann J, Fa\u00dfbender K, Schwiertz A, Sch\u00e4fer KH (2016) Short chain fatty acids and gut microbiota differ between patients with Parkinson\u2019s disease and age-matched controls. Parkinsonism Relat Disord 32:66\u201372. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.08.019","journal-title":"Parkinsonism Relat Disord"},{"key":"11014_CR65","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/ana.25982","volume":"89","author":"AH Tan","year":"2021","unstructured":"Tan AH, Chong CW, Lim SY, Yap IKS, Teh CSJ, Loke MF, Song SL, Tan JY, Ang BH, Tan YQ, Kho MT, Bowman J, Mahadeva S, Yong HS, Lang AE (2021) Gut microbial ecosystem in Parkinson disease: new clinicobiological insights from multi-omics. Ann Neurol 89:546\u2013559. https:\/\/doi.org\/10.1002\/ana.25982","journal-title":"Ann Neurol"},{"key":"11014_CR66","doi-asserted-by":"publisher","DOI":"10.1126\/SCIENCE.AAU6323","author":"VM Rekdal","year":"2019","unstructured":"Rekdal VM, Bess EN, Bisanz JE, Turnbaugh PJ, Balskus EP (2019) Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science. https:\/\/doi.org\/10.1126\/SCIENCE.AAU6323","journal-title":"Science"},{"key":"11014_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187307","volume":"12","author":"T Minato","year":"2017","unstructured":"Minato T, Maeda T, Fujisawa Y, Tsuji H, Nomoto K, Ohno K, Hirayama M (2017) Progression of Parkinson\u2019s disease is associated with gut dysbiosis: two-year follow-up study. PLoS One 12:e0187307. https:\/\/doi.org\/10.1371\/journal.pone.0187307","journal-title":"PLoS One"},{"key":"11014_CR68","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1093\/brain\/awaa201","volume":"143","author":"Y Qian","year":"2020","unstructured":"Qian Y, Yang X, Xu S, Huang P, Li B, Du J, He Y, Su B, Xu LM, Wang L, Huang R, Chen S, Xiao Q (2020) Gut metagenomics-derived genes as potential biomarkers of Parkinson\u2019s disease. Brain 143:2474\u20132489. https:\/\/doi.org\/10.1093\/brain\/awaa201","journal-title":"Brain"},{"key":"11014_CR69","doi-asserted-by":"publisher","first-page":"30","DOI":"10.5056\/jnm17105","volume":"24","author":"AT Nair","year":"2018","unstructured":"Nair AT, Ramachandran V, Joghee NM, Antony S, Ramalingam G (2018) Gut microbiota dysfunction as reliable non-invasive early diagnostic biomarkers in the pathophysiology of Parkinson\u2019s disease: a critical review. J Neurogastroenterol Motil 24:30\u201342. https:\/\/doi.org\/10.5056\/jnm17105","journal-title":"J Neurogastroenterol Motil"},{"key":"11014_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-021-00427-6","volume":"16","author":"VTE Aho","year":"2021","unstructured":"Aho VTE, Houser MC, Pereira PAB, Chang J, Rudi K, Paulin L, Hertzberg V, Auvinen P, Tansey MG, Scheperjans F (2021) Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson\u2019s disease. Mol Neurodegener 16:6. https:\/\/doi.org\/10.1186\/s13024-021-00427-6","journal-title":"Mol Neurodegener"},{"key":"11014_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.614828","volume":"14","author":"N Reich","year":"2020","unstructured":"Reich N, H\u00f6lscher C (2020) Acylated ghrelin as a multi-targeted therapy for Alzheimer\u2019s and Parkinson\u2019s disease. Front Neurosci 14:614828. https:\/\/doi.org\/10.3389\/fnins.2020.614828","journal-title":"Front Neurosci"},{"key":"11014_CR72","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/mds.28016","volume":"35","author":"C Shin","year":"2020","unstructured":"Shin C, Lim Y, Lim H, Ahn TB (2020) Plasma short-chain fatty acids in patients with Parkinson\u2019s disease. Mov Disord 35:1021\u20131027. https:\/\/doi.org\/10.1002\/mds.28016","journal-title":"Mov Disord"},{"key":"11014_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02544-7","volume":"22","author":"G Wu","year":"2022","unstructured":"Wu G, Jiang Z, Pu Y, Chen S, Wang T, Wang Y, Xu X, Wang S, Jin M, Yao Y, Liu Y, Ke S, Liu S (2022) Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson\u2019s disease patients. BMC Neurol 22:13. https:\/\/doi.org\/10.1186\/s12883-021-02544-7","journal-title":"BMC Neurol"},{"key":"11014_CR74","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/jdi.12762","volume":"9","author":"S Yamane","year":"2018","unstructured":"Yamane S, Inagaki N (2018) Regulation of glucagon-like peptide-1 sensitivity by gut microbiota dysbiosis. J Diabetes Investig 9:262\u2013264. https:\/\/doi.org\/10.1111\/jdi.12762","journal-title":"J Diabetes Investig"},{"key":"11014_CR75","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","volume":"21","author":"D Athauda","year":"2016","unstructured":"Athauda D, Foltynie T (2016) The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson\u2019s disease: mechanisms of action. Drug Discov Today 21:802\u2013818. https:\/\/doi.org\/10.1016\/j.drudis.2016.01.013","journal-title":"Drug Discov Today"},{"key":"11014_CR76","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.parkreldis.2018.05.007","volume":"53","author":"A Lin","year":"2018","unstructured":"Lin A, Zheng W, He Y, Tang W, Wei X, He R, Huang W, Su Y, Huang Y, Zhou H, Xie H (2018) Gut microbiota in patients with Parkinson\u2019s disease in southern China. Parkinsonism Relat Disord 53:82\u201388. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.05.007","journal-title":"Parkinsonism Relat Disord"},{"key":"11014_CR77","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.clnu.2018.05.018","volume":"38","author":"OR Tamtaji","year":"2019","unstructured":"Tamtaji OR, Taghizadeh M, Daneshvar Kakhaki R, Kouchaki E, Bahmani F, Borzabadi S, Oryan S, Mafi A, Asemi Z (2019) Clinical and metabolic response to probiotic administration in people with Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled trial. Clin Nutr 38:1031\u20131035. https:\/\/doi.org\/10.1016\/j.clnu.2018.05.018","journal-title":"Clin Nutr"},{"key":"11014_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/BRAINSCI10040206","author":"TH Hsieh","year":"2020","unstructured":"Hsieh TH, Kuo CW, Hsieh KH, Shieh MJ, Peng CW, Chen YC, Chang YL, Huang YZ, Chen CC, Chang PK, Chen KY, Chen HY (2020) Probiotics alleviate the progressive deterioration of motor functions in a mouse model of Parkinson\u2019s disease. Brain Sci. https:\/\/doi.org\/10.3390\/BRAINSCI10040206","journal-title":"Brain Sci"},{"key":"11014_CR79","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/mds.26942","volume":"32","author":"EM Hill-Burns","year":"2017","unstructured":"Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, Peddada SD, Factor SA, Molho E, Zabetian CP, Knight R, Payami H (2017) Parkinson\u2019s disease and Parkinson\u2019s disease medications have distinct signatures of the gut microbiome. Mov Disord 32:739\u2013749. https:\/\/doi.org\/10.1002\/mds.26942","journal-title":"Mov Disord"},{"key":"11014_CR80","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/J.EBIOM.2019.08.048","volume":"47","author":"H Zhong","year":"2019","unstructured":"Zhong H, Ren H, Lu Y, Fang C, Hou G, Yang Z, Chen B, Yang F, Zhao Y, Shi Z, Zhou B, Wu J, Zou H, Zi J, Chen J, Bao X, Hu Y, Gao Y, Zhang J, Xu X, Hou Y, Yang H, Wang J, Liu S, Jia H, Madsen L, Brix S, Kristiansen K, Liu F, Li J (2019) Distinct gut metagenomics and metaproteomics signatures in prediabetics and treatment-na\u00efve type 2 diabetics. EBioMedicine 47:373. https:\/\/doi.org\/10.1016\/J.EBIOM.2019.08.048","journal-title":"EBioMedicine"},{"issue":"1","key":"11014_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-025-00894-4","volume":"11","author":"ME Krueger","year":"2025","unstructured":"Krueger ME, Boles JS, Simon ZD, Alvarez SD, McFarland NR, Okun MS, Zimmermann EM, Forsmark CE, Tansey MG (2025) Comparative analysis of Parkinson\u2019s and inflammatory bowel disease gut microbiomes reveals shared butyrate-producing bacteria depletion. NPJ Parkinsons Dis 11(1):11. https:\/\/doi.org\/10.1038\/s41531-025-00894-4","journal-title":"NPJ Parkinsons Dis"},{"key":"11014_CR82","doi-asserted-by":"publisher","first-page":"e848","DOI":"10.1212\/WNL.0000000000013225","volume":"98","author":"SJ Chen","year":"2022","unstructured":"Chen SJ, Chen CC, Liao HY, Lin YT, Wu YW, Liou JM, Wu MS, Kuo CH, Lin CH (2022) Association of fecal and plasma levels of short-chain fatty acids with gut microbiota and clinical severity in patients with Parkinson disease. Neurology 98:e848\u2013e858. https:\/\/doi.org\/10.1212\/WNL.0000000000013225","journal-title":"Neurology"},{"key":"11014_CR83","doi-asserted-by":"publisher","first-page":"599","DOI":"10.38212\/2224-6614.3484","volume":"31","author":"CY Tsai","year":"2023","unstructured":"Tsai CY, Liu PY, Huang MC, Chang CI, Chen HY, Chou YH, Tsai CN, Lin CH (2023) Abundance of prevotella copri in gut microbiota is inversely related to a healthy diet in patients with type 2 diabetes. J Food Drug Anal 31:599. https:\/\/doi.org\/10.38212\/2224-6614.3484","journal-title":"J Food Drug Anal"},{"key":"11014_CR84","doi-asserted-by":"publisher","first-page":"E1654","DOI":"10.1212\/WNL.0000000000005475","volume":"90","author":"G Pagano","year":"2018","unstructured":"Pagano G, Polychronis S, Wilson H, Giordano B, Ferrara N, Niccolini F, Politis M (2018) Diabetes mellitus and Parkinson disease. Neurology 90:E1654\u2013E1662. https:\/\/doi.org\/10.1212\/WNL.0000000000005475","journal-title":"Neurology"},{"key":"11014_CR85","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.molmed.2013.01.002","volume":"19","author":"JA Santiago","year":"2013","unstructured":"Santiago JA, Potashkin JA (2013) Shared dysregulated pathways lead to Parkinson\u2019s disease and diabetes. Trends Mol Med 19:176\u2013186. https:\/\/doi.org\/10.1016\/j.molmed.2013.01.002","journal-title":"Trends Mol Med"},{"key":"11014_CR86","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/MED.21987","volume":"44","author":"RS Patil","year":"2024","unstructured":"Patil RS, Tupe RS (2024) Communal interaction of glycation and gut microbes in diabetes mellitus, Alzheimer\u2019s disease, and Parkinson\u2019s disease pathogenesis. Med Res Rev 44:365\u2013405. https:\/\/doi.org\/10.1002\/MED.21987","journal-title":"Med Res Rev"},{"key":"11014_CR87","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3109\/00207459309003322","volume":"69","author":"R Sandyk","year":"1993","unstructured":"Sandyk R (1993) The relationship between diabetes mellitus and Parkinson\u2019s disease. Int J Neurosci 69:125\u2013130. https:\/\/doi.org\/10.3109\/00207459309003322","journal-title":"Int J Neurosci"},{"key":"11014_CR88","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.parkreldis.2018.05.026","volume":"55","author":"A Marques","year":"2018","unstructured":"Marques A, Dutheil F, Durand E, Rieu I, Mulliez A, Fantini ML, Boirie Y, Durif F (2018) Glucose dysregulation in Parkinson\u2019s disease: too much glucose or not enough insulin? Parkinsonism Relat Disord 55:122\u2013127. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.05.026","journal-title":"Parkinsonism Relat Disord"},{"key":"11014_CR89","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.tins.2007.06.004","volume":"30","author":"RD Palmiter","year":"2007","unstructured":"Palmiter RD (2007) Is dopamine a physiologically relevant mediator of feeding behavior? Trends Neurosci 30:375\u2013381. https:\/\/doi.org\/10.1016\/j.tins.2007.06.004","journal-title":"Trends Neurosci"},{"key":"11014_CR90","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3233\/JPD-191900","volume":"10","author":"JLY Cheong","year":"2020","unstructured":"Cheong JLY, de Pablo-Fernanz E, Foltynie T, Noyce AJ (2020) The association between type 2 diabetes mellitus and Parkinson\u2019s disease. J Parkinsons Dis 10:775\u2013789. https:\/\/doi.org\/10.3233\/JPD-191900","journal-title":"J Parkinsons Dis"},{"key":"11014_CR91","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/S11910-022-01196-5","volume":"22","author":"RA Manfready","year":"2022","unstructured":"Manfready RA, Forsyth CB, Voigt RM, Hall DA, Goetz CG, Keshavarzian A (2022) Gut-brain communication in Parkinson\u2019s disease: enteroendocrine regulation by GLP-1. Curr Neurol Neurosci Rep 22:335\u2013342. https:\/\/doi.org\/10.1007\/S11910-022-01196-5","journal-title":"Curr Neurol Neurosci Rep"},{"key":"11014_CR92","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10654-023-00970-0","volume":"38","author":"D Aune","year":"2023","unstructured":"Aune D, Schlesinger S, Mahamat-Saleh Y, Zheng B, Udeh-Momoh CT, Middleton LT (2023) Diabetes mellitus, prediabetes and the risk of Parkinson\u2019s disease: a systematic review and meta-analysis of 15 cohort studies with 29.9\u00a0million participants and 86,345 cases. Eur J Epidemiol 38:591. https:\/\/doi.org\/10.1007\/s10654-023-00970-0","journal-title":"Eur J Epidemiol"},{"key":"11014_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2024.1408053","volume":"15","author":"RY Zhang","year":"2024","unstructured":"Zhang RY, Li JY, Liu YN, Zhang ZX, Zhao J, Li FJ (2024) The causal relationship between type 2 diabetes mellitus and isolated REM sleep behavior disorder: results from multivariable and network Mendelian randomization analysis. Front Endocrinol 15:1408053. https:\/\/doi.org\/10.3389\/FENDO.2024.1408053","journal-title":"Front Endocrinol"},{"key":"11014_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/FMICB.2023.1184734","volume":"14","author":"H Li","year":"2023","unstructured":"Li H, Li C (2023) Causal relationship between gut microbiota and type 2 diabetes: a two-sample Mendelian randomization study. Front Microbiol 14:1184734. https:\/\/doi.org\/10.3389\/FMICB.2023.1184734","journal-title":"Front Microbiol"},{"key":"11014_CR95","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/MDS.28551","volume":"36","author":"H Chohan","year":"2021","unstructured":"Chohan H, Senkevich K, Patel RK, Bestwick JP, Jacobs BM, Bandres Ciga S, Gan-Or Z, Noyce AJ (2021) Type 2 diabetes as a determinant of Parkinson\u2019s disease risk and progression. Mov Disord 36:1420. https:\/\/doi.org\/10.1002\/MDS.28551","journal-title":"Mov Disord"},{"key":"11014_CR96","unstructured":"(2018) T. incidence, prevalence of Parkinson\u2019. In the UK, Retrieved from London, UK. https:\/\/www.parkinsons.org.uk\/professionals\/resources\/parkinsons-prevalence-uk"},{"key":"11014_CR97","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1474-4422(04)00681-7","volume":"3","author":"S Craft","year":"2004","unstructured":"Craft S, Watson GS (2004) Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3:169\u2013178. https:\/\/doi.org\/10.1016\/S1474-4422(04)00681-7","journal-title":"Lancet Neurol"},{"key":"11014_CR98","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.parkreldis.2018.08.023","volume":"64","author":"SJ Chung","year":"2019","unstructured":"Chung SJ, Jeon S, Yoo HS, Kim G, Oh JS, Kim JS, Evans AC, Sohn YH, Lee PH (2019) Detrimental effect of type 2 diabetes mellitus in a large case series of Parkinson\u2019s disease. Parkinsonism Relat Disord 64:54\u201359. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.08.023","journal-title":"Parkinsonism Relat Disord"},{"key":"11014_CR99","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.parkreldis.2014.10.008","volume":"20","author":"NI Bohnen","year":"2014","unstructured":"Bohnen NI, Kotagal V, M\u00fcller MLTM, Koeppe RA, Scott PJH, Albin RL, Frey KA, Petrou M (2014) Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. Parkinsonism Relat Disord 20:1394\u20131398. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.10.008","journal-title":"Parkinsonism Relat Disord"},{"key":"11014_CR100","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-021-01171-0","volume":"9","author":"I Martinez-Valbuena","year":"2021","unstructured":"Martinez-Valbuena I, Valenti-Azcarate R, Amat-Villegas I, Marcilla I, Marti-Andres G, Caballero MC, Riverol M, Tu\u00f1on MT, Fraser PE, Luquin MR (2021) Mixed pathologies in pancreatic \u03b2 cells from subjects with neurodegenerative diseases and their interaction with prion protein. Acta Neuropathol Commun 9:64. https:\/\/doi.org\/10.1186\/s40478-021-01171-0","journal-title":"Acta Neuropathol Commun"},{"key":"11014_CR101","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1021\/acs.chemrev.0c00981","volume":"121","author":"D Milardi","year":"2021","unstructured":"Milardi D, Gazit E, Radford SE, Xu Y, Gallardo RU, Caflisch A, Westermark GT, Westermark P, La Rosa C, Ramamoorthy A (2021) Proteostasis of islet amyloid polypeptide: a molecular perspective of risk factors and protective strategies for type II diabetes. Chem Rev 121:1845\u20131893. https:\/\/doi.org\/10.1021\/acs.chemrev.0c00981","journal-title":"Chem Rev"},{"key":"11014_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101546","author":"A Sharma","year":"2020","unstructured":"Sharma A, Weber D, Raupbach J, Dakal TC, Flie\u00dfbach K, Ramirez A, Grune T, W\u00fcllner U (2020) Advanced glycation end products and protein carbonyl levels in plasma reveal sex-specific differences in Parkinson\u2019s and Alzheimer\u2019s disease. Redox Biol. https:\/\/doi.org\/10.1016\/j.redox.2020.101546","journal-title":"Redox Biol"},{"key":"11014_CR103","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1212\/WNL.0000000000005771","volume":"91","author":"E De Pablo-Fernandez","year":"2018","unstructured":"De Pablo-Fernandez E, Goldacre R, Pakpoor J, Noyce AJ, Warner TT (2018) Association between diabetes and subsequent Parkinson disease: a record-linkage cohort study. Neurology 91:e139\u2013e142. https:\/\/doi.org\/10.1212\/WNL.0000000000005771","journal-title":"Neurology"},{"key":"11014_CR104","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005921","volume":"96","author":"YW Yang","year":"2017","unstructured":"Yang YW, Hsieh TF, Li CI, Liu CS, Lin WY, Chiang JH, Li TC, Lin CC (2017) Increased risk of Parkinson disease with diabetes mellitus in a population-based study. Medicine (Baltimore) 96:e5921. https:\/\/doi.org\/10.1097\/MD.0000000000005921","journal-title":"Medicine (Baltimore)"},{"key":"11014_CR105","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003549","volume":"95","author":"X Yue","year":"2016","unstructured":"Yue X, Li H, Yan H, Zhang P, Chang L, Li T (2016) Risk of Parkinson disease in diabetes mellitus: an updated meta-analysis of population-based cohort studies. Medicine (Baltimore) 95:e3549. https:\/\/doi.org\/10.1097\/MD.0000000000003549","journal-title":"Medicine (Baltimore)"},{"key":"11014_CR106","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2337\/dc11-1511","volume":"35","author":"Y Sun","year":"2012","unstructured":"Sun Y, Chang YH, Chen HF, Su YH, Su HF, Li CY (2012) Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications. Diabetes Care 35:1047\u20131049. https:\/\/doi.org\/10.2337\/dc11-1511","journal-title":"Diabetes Care"},{"key":"11014_CR107","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.neuroscience.2014.04.006","volume":"270","author":"JK Morris","year":"2014","unstructured":"Morris JK, Vidoni ED, Perea RD, Rada R, Johnson DK, Lyons K, Pahwa R, Burns JM, Honea RA (2014) Insulin resistance and gray matter volume in neurodegenerative disease. Neuroscience 270:139\u2013147. https:\/\/doi.org\/10.1016\/j.neuroscience.2014.04.006","journal-title":"Neuroscience"},{"key":"11014_CR108","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1463-1326.2008.01018.x","volume":"11","author":"R Gentilella","year":"2009","unstructured":"Gentilella R, Bianchi C, Rossi A, Rotella CM (2009) Exenatide: a review from pharmacology to clinical practice. Diabetes Obes Metab 11:544\u2013556. https:\/\/doi.org\/10.1111\/j.1463-1326.2008.01018.x","journal-title":"Diabetes Obes Metab"},{"key":"11014_CR109","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.parkreldis.2021.06.002","volume":"89","author":"A S\u00e1nchez-G\u00f3mez","year":"2021","unstructured":"S\u00e1nchez-G\u00f3mez A, D\u00edaz Y, Duarte-Salles T, Compta Y, Mart\u00ed MJ (2021) Prediabetes, type 2 diabetes mellitus and risk of Parkinson\u2019s disease: a population-based cohort study. Parkinsonism Relat Disord 89:22\u201327. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.06.002","journal-title":"Parkinsonism Relat Disord"},{"key":"11014_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyw047","volume":"19","author":"M Lu","year":"2016","unstructured":"Lu M, Su C, Qiao C, Bian Y, Ding J, Hu G (2016) Metformin prevents dopaminergic neuron death in MPTP\/P-induced mouse model of Parkinson\u2019s disease via autophagy and mitochondrial ROS clearance. Int J Neuropsychopharmacol 19:1\u201311. https:\/\/doi.org\/10.1093\/ijnp\/pyw047","journal-title":"Int J Neuropsychopharmacol"},{"key":"11014_CR111","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.pneurobio.2016.10.001","volume":"145\u2013146","author":"D Athauda","year":"2016","unstructured":"Athauda D, Foltynie T (2016) Insulin resistance and Parkinson\u2019s disease: a new target for disease modification? Prog Neurobiol 145\u2013146:98\u2013120. https:\/\/doi.org\/10.1016\/j.pneurobio.2016.10.001","journal-title":"Prog Neurobiol"},{"key":"11014_CR112","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1515\/revneuro-2013-0050","volume":"25","author":"D Najem","year":"2014","unstructured":"Najem D, Bamji-Mirza M, Chang N, Liu QY, Zhang W (2014) Insulin resistance, neuroinflammation, and Alzheimer\u2019s disease. Rev Neurosci 25:509\u2013525. https:\/\/doi.org\/10.1515\/revneuro-2013-0050","journal-title":"Rev Neurosci"},{"key":"11014_CR113","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.conb.2017.08.004","volume":"48","author":"S Zhai","year":"2018","unstructured":"Zhai S, Tanimura A, Graves SM, Shen W, Surmeier DJ (2018) Striatal synapses, circuits, and Parkinson\u2019s disease. Curr Opin Neurobiol 48:9\u201316. https:\/\/doi.org\/10.1016\/j.conb.2017.08.004","journal-title":"Curr Opin Neurobiol"},{"key":"11014_CR114","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jphs.2020.07.011","volume":"144","author":"L Iovino","year":"2020","unstructured":"Iovino L, Tremblay ME, Civiero L (2020) Glutamate-induced excitotoxicity in Parkinson\u2019s disease: the role of glial cells. J Pharmacol Sci 144:151\u2013164. https:\/\/doi.org\/10.1016\/j.jphs.2020.07.011","journal-title":"J Pharmacol Sci"},{"key":"11014_CR115","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s13668-019-0276-z","volume":"8","author":"A Kleinridders","year":"2019","unstructured":"Kleinridders A, Pothos EN (2019) Impact of brain insulin signaling on dopamine function, food intake, reward, and emotional behavior. Curr Nutr Rep 8:83\u201391. https:\/\/doi.org\/10.1007\/s13668-019-0276-z","journal-title":"Curr Nutr Rep"},{"key":"11014_CR116","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0304-3940(96)12357-0","volume":"204","author":"M Takahashi","year":"1996","unstructured":"Takahashi M, Yamada T, Tooyama I, Moroo I, Kimura H, Yamamoto T, Okada H (1996) Insulin receptor mRNA in the substantia nigra in Parkinson\u2019s disease. Neurosci Lett 204:201\u2013204. https:\/\/doi.org\/10.1016\/0304-3940(96)12357-0","journal-title":"Neurosci Lett"},{"key":"11014_CR117","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3233\/JPD-202085","volume":"10","author":"T Werner","year":"2020","unstructured":"Werner T, Horvath I, Wittung-Stafshede P (2020) Crosstalk between alpha-synuclein and other human and non-human amyloidogenic proteins: consequences for amyloid formation in Parkinson\u2019s disease. J Parkinsons Dis 10:819\u2013830. https:\/\/doi.org\/10.3233\/JPD-202085","journal-title":"J Parkinsons Dis"},{"key":"11014_CR118","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/MDS.26566","volume":"31","author":"H Vicente Miranda","year":"2016","unstructured":"Vicente Miranda H, El-Agnaf OMA, Outeiro TF (2016) Glycation in Parkinson\u2019s disease and Alzheimer\u2019s disease. Mov Disord 31:782\u2013790. https:\/\/doi.org\/10.1002\/MDS.26566","journal-title":"Mov Disord"},{"key":"11014_CR119","doi-asserted-by":"publisher","first-page":"151","DOI":"10.18926\/AMO\/54413","volume":"70","author":"J Wada","year":"2016","unstructured":"Wada J, Nakatsuka A (2016) Mitochondrial dynamics and mitochondrial dysfunction in diabetes. Acta Med Okayama 70:151\u2013158. https:\/\/doi.org\/10.18926\/AMO\/54413","journal-title":"Acta Med Okayama"},{"key":"11014_CR120","doi-asserted-by":"publisher","first-page":"8754","DOI":"10.1007\/s12035-018-1025-9","volume":"55","author":"A Biosa","year":"2018","unstructured":"Biosa A, Outeiro TF, Bubacco L, Bisaglia M (2018) Diabetes mellitus as a risk factor for Parkinson\u2019s disease: a molecular point of view. Mol Neurobiol 55:8754\u20138763. https:\/\/doi.org\/10.1007\/s12035-018-1025-9","journal-title":"Mol Neurobiol"},{"key":"11014_CR121","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1002\/jnr.21644","volume":"86","author":"S Shaikh","year":"2008","unstructured":"Shaikh S, Nicholson LFB (2008) Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation. J Neurosci Res 86:2071\u20132082. https:\/\/doi.org\/10.1002\/jnr.21644","journal-title":"J Neurosci Res"},{"key":"11014_CR122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2012.02.018","volume":"317","author":"J Li","year":"2012","unstructured":"Li J, Liu D, Sun L, Lu Y, Zhang Z (2012) Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective. J Neurol Sci 317:1\u20135. https:\/\/doi.org\/10.1016\/j.jns.2012.02.018","journal-title":"J Neurol Sci"},{"key":"11014_CR123","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1007\/s10571-021-01145-9","volume":"42","author":"BP Gaire","year":"2022","unstructured":"Gaire BP (2022) Microglia as the critical regulators of neuroprotection and functional recovery in cerebral ischemia. Cell Mol Neurobiol 42:2505\u20132525. https:\/\/doi.org\/10.1007\/s10571-021-01145-9","journal-title":"Cell Mol Neurobiol"},{"key":"11014_CR124","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/aje\/kwm260","volume":"167","author":"H Chen","year":"2008","unstructured":"Chen H, O\u2019Reilly EJ, Schwarzschild MA, Ascherio A (2008) Peripheral inflammatory biomarkers and risk of Parkinson\u2019s disease. Am J Epidemiol 167:90\u201395. https:\/\/doi.org\/10.1093\/aje\/kwm260","journal-title":"Am J Epidemiol"},{"key":"11014_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/nutd.2017.10","volume":"7","author":"R Maldonado-Ruiz","year":"2017","unstructured":"Maldonado-Ruiz R, Montalvo-Mart\u00ednez L, Fuentes-Mera L, Camacho A (2017) Microglia activation due to obesity programs metabolic failure leading to type two diabetes. Nutr Diabetes 7:e254. https:\/\/doi.org\/10.1038\/nutd.2017.10","journal-title":"Nutr Diabetes"},{"key":"11014_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.119095","author":"Y Wang","year":"2025","unstructured":"Wang Y, Gao P, Wu Z, Jiang B, Wang Y, He Z, Zhao B, Tian X, Gao H, Cai L, Li W (2025) Exploring the therapeutic potential of Chinese herbs on comorbid type 2 diabetes mellitus and Parkinson\u2019s disease: a mechanistic study. J Ethnopharmacol. https:\/\/doi.org\/10.1016\/j.jep.2024.119095","journal-title":"J Ethnopharmacol"},{"key":"11014_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/J.DSCB.2024.100158","volume":"15","author":"MA Bantounou","year":"2024","unstructured":"Bantounou MA, Shoaib K, Mazzoleni A, Modalavalasa H, Kumar N, Philip S (2024) The association between type 2 diabetes mellitus and Parkinson\u2019s disease; a systematic review and meta-analysis. Brain Disorders 15:100158. https:\/\/doi.org\/10.1016\/J.DSCB.2024.100158","journal-title":"Brain Disorders"},{"key":"11014_CR128","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3390\/nu5030829","volume":"5","author":"AM Caricilli","year":"2013","unstructured":"Caricilli AM, Saad MJA (2013) The role of gut microbiota on insulin resistance. Nutrients 5:829. https:\/\/doi.org\/10.3390\/nu5030829","journal-title":"Nutrients"},{"key":"11014_CR129","doi-asserted-by":"publisher","DOI":"10.3390\/CELLS9030740","author":"CT Hong","year":"2020","unstructured":"Hong CT, Chen KY, Wang W, Chiu JY, Wu D, Chao TY, Hu CJ, Chau KYD, Bamodu OA (2020) Insulin resistance promotes Parkinson\u2019s disease through aberrant expression of \u03b1-synuclein, mitochondrial dysfunction, and deregulation of the polo-like kinase 2 signaling. Cells. https:\/\/doi.org\/10.3390\/CELLS9030740","journal-title":"Cells"},{"key":"11014_CR130","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/S41401-020-0454-Y","volume":"42","author":"YL Guo","year":"2021","unstructured":"Guo YL, Duan WJ, Lu DH, Ma XH, Li XX, Li Z, Bi W, Kurihara H, Liu HZ, Li YF, He RR (2021) Autophagy-dependent removal of \u03b1-synuclein: a novel mechanism of GM1 ganglioside neuroprotection against Parkinson\u2019s disease. Acta Pharmacol Sin 42:518\u2013528. https:\/\/doi.org\/10.1038\/S41401-020-0454-Y","journal-title":"Acta Pharmacol Sin"},{"key":"11014_CR131","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/J.JNS.2011.12.008","volume":"315","author":"D Bosco","year":"2012","unstructured":"Bosco D, Plastino M, Cristiano D, Colica C, Ermio C, De Bartolo M, Mungari P, Fonte G, Consoli D, Consoli A, Fava A (2012) Dementia is associated with insulin resistance in patients with Parkinson\u2019s disease. J Neurol Sci 315:39\u201343. https:\/\/doi.org\/10.1016\/J.JNS.2011.12.008","journal-title":"J Neurol Sci"},{"key":"11014_CR132","doi-asserted-by":"publisher","DOI":"10.3389\/FNINS.2019.00868","volume":"13","author":"F Fiory","year":"2019","unstructured":"Fiory F, Perruolo G, Cimmino I, Cabaro S, Pignalosa FC, Miele C, Beguinot F, Formisano P, Oriente F (2019) The relevance of insulin action in the dopaminergic system. Front Neurosci 13:868. https:\/\/doi.org\/10.3389\/FNINS.2019.00868","journal-title":"Front Neurosci"},{"key":"11014_CR133","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3233\/JAD-2011-101524","volume":"24","author":"CC Hsu","year":"2011","unstructured":"Hsu CC, Wahlqvist ML, Lee MS, Tsai HN (2011) Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis 24:485\u2013493. https:\/\/doi.org\/10.3233\/JAD-2011-101524","journal-title":"J Alzheimers Dis"},{"key":"11014_CR134","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/J.PNPBP.2017.06.002","volume":"79","author":"YC Kuan","year":"2017","unstructured":"Kuan YC, Huang KW, Lin CL, Hu CJ, Kao CH (2017) Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus. Prog Neuropsychopharmacol Biol Psychiatry 79:77\u201383. https:\/\/doi.org\/10.1016\/J.PNPBP.2017.06.002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"11014_CR135","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS23010398","author":"F Agostini","year":"2021","unstructured":"Agostini F, Masato A, Bubacco L, Bisaglia M (2021) Metformin Repurposing for Parkinson Disease therapy: opportunities and challenges. Int J Mol Sci. https:\/\/doi.org\/10.3390\/IJMS23010398","journal-title":"Int J Mol Sci"},{"key":"11014_CR136","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.neuropharm.2018.01.040","volume":"136","author":"C H\u00f6lscher","year":"2018","unstructured":"H\u00f6lscher C (2018) Novel dual GLP-1\/GIP receptor agonists show neuroprotective effects in Alzheimer\u2019s and Parkinson\u2019s disease models. Neuropharmacology 136:251\u2013259. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.01.040","journal-title":"Neuropharmacology"},{"key":"11014_CR137","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T (2017) Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390:1664\u20131675. https:\/\/doi.org\/10.1016\/S0140-6736(17)31585-4","journal-title":"Lancet"},{"key":"11014_CR138","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.neuropharm.2017.09.023","volume":"136","author":"D Athauda","year":"2018","unstructured":"Athauda D, Foltynie T (2018) Protective effects of the GLP-1 mimetic exendin-4 in Parkinson\u2019s disease. Neuropharmacology 136:260\u2013270. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.09.023","journal-title":"Neuropharmacology"},{"key":"11014_CR139","doi-asserted-by":"publisher","first-page":"25088","DOI":"10.1074\/jbc.M113.452516","volume":"288","author":"H Yadav","year":"2013","unstructured":"Yadav H, Lee JH, Lloyd J, Walter P, Rane SG (2013) Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem 288:25088\u201325097. https:\/\/doi.org\/10.1074\/jbc.M113.452516","journal-title":"J Biol Chem"},{"key":"11014_CR140","doi-asserted-by":"publisher","DOI":"10.3390\/ANTIOX10121935","volume":"10","author":"KJ Lin","year":"2021","unstructured":"Lin KJ, Wang TJ, Chen SD, Lin KL, Liou CW, Lan MY, Chuang YC, Chuang JH, Wang PW, Lee JJ, Wang FS, Lin HY, Lin TK (2021) Two birds one stone: the neuroprotective effect of antidiabetic agents on parkinson disease\u2014focus on sodium-glucose cotransporter 2 (SGLT2) inhibitors. Antioxidants 10:1935. https:\/\/doi.org\/10.3390\/ANTIOX10121935","journal-title":"Antioxidants"},{"key":"11014_CR141","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2022.937555","author":"M Zhu","year":"2022","unstructured":"Zhu M, Liu X, Ye Y, Yan X, Cheng Y, Zhao L, Chen F, Ling Z (2022) Gut microbiota: a novel therapeutic target for Parkinson\u2019s disease. Front Immunol. https:\/\/doi.org\/10.3389\/FIMMU.2022.937555","journal-title":"Front Immunol"},{"key":"11014_CR142","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","volume":"405","author":"N Vijiaratnam","year":"2025","unstructured":"Vijiaratnam N, Girges C, Auld G, McComish R, King A, Skene SS, Hibbert S, Wong A, Melander S, Gibson R, Matthews H, Dickson J, Carroll C, Patrick A, Inches J, Silverdale M, Blackledge B, Whiston J, Hu M, Welch J, Duncan G, Power K, Gallen S, Kerr J, Chaudhuri KR, Batzu L, Rota S, Jabbari E, Morris H, Limousin P, Greig N, Li Y, Libri V, Gandhi S, Athauda D, Chowdhury K, Foltynie T (2025) Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet 405:627\u2013636. https:\/\/doi.org\/10.1016\/S0140-6736(24)02808-3","journal-title":"Lancet"},{"key":"11014_CR143","doi-asserted-by":"publisher","unstructured":"Ibrahim R, Kambal A, Abdelmajeed MA, Ibrahim R, Kambal A, Abdelmajeed MA (2025) Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: a comprehensive review. Cureus 17. https:\/\/doi.org\/10.7759\/CUREUS.92441","DOI":"10.7759\/CUREUS.92441"},{"key":"11014_CR144","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1462240","volume":"15","author":"D Lv","year":"2024","unstructured":"Lv D, Feng P, Guan X, Liu Z, Li D, Xue C, Bai B, H\u00f6lscher C (2024) Neuroprotective effects of GLP-1 class drugs in Parkinson\u2019s disease. Front Neurol 15:1462240. https:\/\/doi.org\/10.3389\/fneur.2024.1462240","journal-title":"Front Neurol"},{"key":"11014_CR145","doi-asserted-by":"publisher","unstructured":"Waseem H, Abideen Z, Ahmad R, Ansari M, Aimen S, Khan M (2025) Efficacy and safety of glucagon-like peptide-1 receptor agonists for Parkinson\u2019s disease: a systematic review and meta-analysis of randomized controlled trials (P11\u20135.012). Neurology 104:4770. https:\/\/doi.org\/10.1212\/wnl.0000000000211906","DOI":"10.1212\/wnl.0000000000211906"},{"key":"11014_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107220","author":"MB de Albuquerque","year":"2025","unstructured":"de Albuquerque MB, Nunes LEDB, de Oliveira Maldonado JV, Melo Ferreira DG, Margato MM, Rabelo LV, Valen\u00e7a MM, Oliveira Cordeiro LH (2025) GLP\u20101 receptor agonists for Parkinson\u2019s disease: an updated meta-analysis. Parkinsonism Relat Disord. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.107220","journal-title":"Parkinsonism Relat Disord"},{"key":"11014_CR147","doi-asserted-by":"publisher","DOI":"10.1177\/1877718X251359391","author":"M Sun","year":"2025","unstructured":"Sun M, Wang X, Lu Z, Yang Y, Lv S, Miao M, Chen W-M, Wu S-Y, Zhang J (2025) SGLT2 inhibitors vs. metformin for Parkinson\u2019s disease risk reduction in type 2 diabetes. J Parkinsons Dis. https:\/\/doi.org\/10.1177\/1877718X251359391","journal-title":"J Parkinsons Dis"},{"key":"11014_CR148","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00832-9","volume":"14","author":"P Kostrzewska","year":"2025","unstructured":"Kostrzewska P, Kuca P, Witek P, Ma\u0142yszko J, Alster NM, Alster P (2025) SGLT-2 inhibitors in the prevention and progression of neurodegenerative diseases: a narrative review. Neurol Ther 14:2295. https:\/\/doi.org\/10.1007\/s40120-025-00832-9","journal-title":"Neurol Ther"},{"key":"11014_CR149","doi-asserted-by":"publisher","unstructured":"Guo J, Tang H, Shao H, Lu Y, Shi L, Fonseca V, Guo Y, Bian J (2024) 916-P: SGLT2 inhibitors and Parkinson\u2019s Disease (PD) risk in older populations with Type 2 Diabetes (T2D). Diabetes 73. https:\/\/doi.org\/10.2337\/db24-916-p","DOI":"10.2337\/db24-916-p"},{"key":"11014_CR150","doi-asserted-by":"publisher","DOI":"10.1186\/S13098-025-01841-2","volume":"17","author":"AR Allam","year":"2025","unstructured":"Allam AR, Helal MB, Alhateem MS, Shehab MA, Elshaar AG, Saeda MA, Ibrahim FM, Khalil AM, Mahmoud AM (2025) Network meta-analysis of randomized control trials evaluating the effectiveness of various probiotic formulations in patients with type 2 diabetes mellitus. Diabetol Metab Syndr 17:265. https:\/\/doi.org\/10.1186\/S13098-025-01841-2","journal-title":"Diabetol Metab Syndr"},{"key":"11014_CR151","doi-asserted-by":"publisher","DOI":"10.1186\/S43556-025-00307-1","volume":"6","author":"C Chen","year":"2025","unstructured":"Chen C, Wang GQ, Di Li D, Zhang F (2025) Microbiota\u2013gut\u2013brain axis in neurodegenerative diseases: molecular mechanisms and therapeutic targets. Mol Biomed 6:64. https:\/\/doi.org\/10.1186\/S43556-025-00307-1","journal-title":"Mol Biomed"},{"key":"11014_CR152","doi-asserted-by":"publisher","DOI":"10.4014\/jmb.2509.09029","volume":"35","author":"H Zhang","year":"2025","unstructured":"Zhang H, Shen C, Lei W, Wang J, Liu J, Qiu Z (2025) Pilot clinical trial of fecal microbiota transplantation for constipation in Parkinson\u2019s disease. J Microbiol Biotechnol 35:e2509029. https:\/\/doi.org\/10.4014\/jmb.2509.09029","journal-title":"J Microbiol Biotechnol"},{"issue":"1","key":"11014_CR153","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-026-02604-9","volume":"11","author":"R Zhang","year":"2026","unstructured":"Zhang R, Feng R, Wang J, Chen Y, Liu H, Zhu Q, Tian H, Qin C, Teng J, Tang B, Wu M, Zeng J, Wu E, Ding X, Wang X (2026) Gut microbiota modulation via repeated donor fecal transplantation improves motor and gastrointestinal symptoms in drug-na\u00efve Parkinson\u2019s disease: a randomized phase 2 trial. Signal Transduct Target Ther 11(1):11. https:\/\/doi.org\/10.1038\/s41392-026-02604-9","journal-title":"Signal Transduct Target Ther"},{"key":"11014_CR154","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1126\/SCIENCE.ABI6087","volume":"374","author":"G Agirman","year":"1979","unstructured":"Agirman G, Yu KB, Hsiao EY (1979) Signaling inflammation across the gut-brain axis. Science 374:1087\u20131092. https:\/\/doi.org\/10.1126\/SCIENCE.ABI6087","journal-title":"Science"},{"key":"11014_CR155","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/CNS.14077","volume":"29","author":"ZH Li","year":"2023","unstructured":"Li ZH, Jiang YY, Long CY, Peng Q, Yue RS (2023) The gut microbiota\u2010astrocyte axis: implications for type 2 diabetic cognitive dysfunction. CNS Neurosci Ther 29:59. https:\/\/doi.org\/10.1111\/CNS.14077","journal-title":"CNS Neurosci Ther"},{"key":"11014_CR156","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s42770-022-00686-5","volume":"53","author":"Y Liu","year":"2022","unstructured":"Liu Y, Zheng S, Cui J, Guo T, Zhang J (2022) Lactiplantibacillus plantarum Y15 alleviate type 2 diabetes in mice via modulating gut microbiota and regulating NF-\u03baB and insulin signaling pathway. Braz J Microbiol 53:935\u2013945. https:\/\/doi.org\/10.1007\/s42770-022-00686-5","journal-title":"Braz J Microbiol"},{"key":"11014_CR157","doi-asserted-by":"publisher","first-page":"9570","DOI":"10.3168\/jds.2019-16840","volume":"102","author":"X Zhou","year":"2019","unstructured":"Zhou X, Liu H, Zhang J, Mu J, Zalan Z, Hegyi F, Tak\u00e1cs K, Zhao X, Du M (2019) Protective effect of Lactobacillus fermentum CQPC04 on dextran sulfate sodium\u2013induced colitis in mice is associated with modulation of the nuclear factor-\u03baB signaling pathway. J Dairy Sci 102:9570\u20139585. https:\/\/doi.org\/10.3168\/jds.2019-16840","journal-title":"J Dairy Sci"},{"key":"11014_CR158","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/1061186X.2022.2144869","volume":"31","author":"Q Meng","year":"2023","unstructured":"Meng Q, Xu Y, Li Y, Wang Y (2023) Novel studies on Drosophila melanogaster model reveal the roles of JNK-Jak\/STAT axis and intestinal microbiota in insulin resistance. J Drug Target 31:261\u2013268. https:\/\/doi.org\/10.1080\/1061186X.2022.2144869","journal-title":"J Drug Target"},{"issue":"1","key":"11014_CR159","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01743-1","volume":"9","author":"JS Loh","year":"2024","unstructured":"Loh JS, Mak WQ, Tan LKS, Ng CX, Chan HH, Yeow SH, Foo JB, Ong YS, How CW, Khaw KY (2024) Microbiota\u2013gut\u2013brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduct Target Ther 9(1):9. https:\/\/doi.org\/10.1038\/s41392-024-01743-1","journal-title":"Signal Transduct Target Ther"},{"key":"11014_CR160","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3233\/JPD-191699","volume":"9","author":"HF Green","year":"2019","unstructured":"Green HF, Khosousi S, Svenningsson P (2019) Plasma IL-6 and IL-17A correlate with severity of motor and non-motor symptoms in Parkinson\u2019s disease. J Parkinsons Dis 9:705\u2013709. https:\/\/doi.org\/10.3233\/JPD-191699","journal-title":"J Parkinsons Dis"},{"key":"11014_CR161","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s12602-011-9080-9","volume":"3","author":"A Zarfeshani","year":"2011","unstructured":"Zarfeshani A, Khaza\u2019ai H, Mohd Ali R, Hambali Z, Wahle KWJ, Mutalib MSA (2011) Effect of lactobacillus casei on the production of pro-inflammatory markers in Streptozotocin-induced diabetic rats. Probiotics Antimicrob Proteins 3:168\u2013174. https:\/\/doi.org\/10.1007\/s12602-011-9080-9","journal-title":"Probiotics Antimicrob Proteins"},{"key":"11014_CR162","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5681\/bi.2014.007","volume":"4","author":"M Mohamadshahi","year":"2014","unstructured":"Mohamadshahi M, Veissi M, Haidari F, Shahbazian H, Kaydani GA, Mohammadi F (2014) Effects of probiotic yogurt consumption on inflammatory biomarkers in patients with type 2 diabetes. Bioimpacts 4:83\u201388. https:\/\/doi.org\/10.5681\/bi.2014.007","journal-title":"Bioimpacts"},{"key":"11014_CR163","doi-asserted-by":"publisher","first-page":"314","DOI":"10.4166\/kjg.2019.74.6.314","volume":"74","author":"B Woldeamlak","year":"2019","unstructured":"Woldeamlak B, Yirdaw K, Biadgo B (2019) Role of gut microbiota in type 2 diabetes mellitus and its complications: novel insights and potential intervention strategies. Korean J Gastroenterol 74:314\u2013320. https:\/\/doi.org\/10.4166\/kjg.2019.74.6.314","journal-title":"Korean J Gastroenterol"},{"key":"11014_CR164","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/bs.pbr.2019.10.006","volume":"252","author":"AM Schonhoff","year":"2020","unstructured":"Schonhoff AM, Williams GP, Wallen ZD, Standaert DG, Harms AS (2020) Innate and adaptive immune responses in Parkinson\u2019s disease. Prog Brain Res 252:169\u2013216. https:\/\/doi.org\/10.1016\/bs.pbr.2019.10.006","journal-title":"Prog Brain Res"},{"key":"11014_CR165","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s11481-019-09888-5","volume":"15","author":"Y Huang","year":"2020","unstructured":"Huang Y, Liu Z, Cao BB, Qiu YH, Peng YP (2020) Treg cells attenuate neuroinflammation and protect neurons in a mouse model of Parkinson\u2019s disease. J Neuroimmune Pharmacol 15:224\u2013237. https:\/\/doi.org\/10.1007\/s11481-019-09888-5","journal-title":"J Neuroimmune Pharmacol"},{"key":"11014_CR166","first-page":"17946","volume":"9","author":"F Yang","year":"2016","unstructured":"Yang F, Li B, Li L, Zhang H (2016) The clinical significance of the imbalance of Th17 and Treg cells and their related cytokines in peripheral blood of Parkinson\u2019s disease patients. Int J Clin Exp Med 9:17946\u201317951","journal-title":"Int J Clin Exp Med"},{"key":"11014_CR167","doi-asserted-by":"publisher","first-page":"31","DOI":"10.21037\/HBSN-20-671","volume":"10","author":"L Sheng","year":"2021","unstructured":"Sheng L, Jena PK, Hu Y, Wan Y-JY (2021) Age-specific microbiota in altering host inflammatory and metabolic signaling as well as metabolome based on the sex. Hepatobiliary Surg Nutr 10:31\u201348. https:\/\/doi.org\/10.21037\/HBSN-20-671","journal-title":"Hepatobiliary Surg Nutr"},{"key":"11014_CR168","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/METABO11010029","volume":"11","author":"P Li","year":"2021","unstructured":"Li P, Killinger BA, Ensink E, Beddows I, Yilmaz A, Lubben N, Lamp J, Schilthuis M, Vega IE, Woltjer R, Pospisilik JA, Brundin P, Brundin L, Graham SF, Labrie V (2021) Gut microbiota dysbiosis is associated with elevated bile acids in Parkinson\u2019s disease. Metabolites 11:1\u201315. https:\/\/doi.org\/10.3390\/METABO11010029","journal-title":"Metabolites"},{"key":"11014_CR169","doi-asserted-by":"publisher","DOI":"10.1186\/S12866-021-02415-8","author":"PJ McMurdie","year":"2022","unstructured":"McMurdie PJ, Stoeva MK, Justice N, Nemchek M, Sieber CMK, Tyagi S, Gines J, Skennerton CT, Souza M, Kolterman O, Eid J (2022) Increased circulating butyrate and ursodeoxycholate during probiotic intervention in humans with type 2 diabetes. BMC Microbiol. https:\/\/doi.org\/10.1186\/S12866-021-02415-8","journal-title":"BMC Microbiol"},{"key":"11014_CR170","doi-asserted-by":"publisher","DOI":"10.17305\/BB.2025.12519","volume":"25","author":"M Rajan","year":"2025","unstructured":"Rajan M, Sivanesan S, Ramachandran K, Goyal P, Palanivelu P, Ghosh A, Vijayaraghavan R, Vasavan SS (2025) TUDCA combined with Syndopa protects the midbrain and gut from MPTP toxicity in a Parkinson\u2019s disease mouse model: immunohistochemical evidence. Biomol Biomed 25:2776. https:\/\/doi.org\/10.17305\/BB.2025.12519","journal-title":"Biomol Biomed"},{"key":"11014_CR171","doi-asserted-by":"publisher","DOI":"10.1016\/J.JSBMB.2025.106877","volume":"255","author":"C Jalili","year":"2026","unstructured":"Jalili C, Hosseinkhani F, Dayer D, Tabandeh MR, Abbasi A, Zamir Nasta T (2026) Indole-3-propionic acid function through PXR and AhR, molecular signaling pathways, and antitoxic role in underlying diseases. J Steroid Biochem Mol Biol 255:106877. https:\/\/doi.org\/10.1016\/J.JSBMB.2025.106877","journal-title":"J Steroid Biochem Mol Biol"},{"key":"11014_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJPHAR.2023.176067","volume":"959","author":"ST Meka","year":"2023","unstructured":"Meka ST, Bojja SL, Kumar G, Birangal SR, Rao CM (2023) Novel HDAC inhibitors provide neuroprotection in MPTP-induced Parkinson\u2019s disease model of rats. Eur J Pharmacol 959:176067. https:\/\/doi.org\/10.1016\/J.EJPHAR.2023.176067","journal-title":"Eur J Pharmacol"},{"key":"11014_CR173","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/327089","volume":"2011","author":"G Bing","year":"2011","unstructured":"Bing G, Liu M (2011) Lipopolysaccharide animal models for Parkinson\u2032s disease. Parkinsons Dis 2011:327089. https:\/\/doi.org\/10.4061\/2011\/327089","journal-title":"Parkinsons Dis"},{"key":"11014_CR174","doi-asserted-by":"publisher","DOI":"10.1016\/J.NBD.2022.105780","volume":"170","author":"RM Voigt","year":"2022","unstructured":"Voigt RM, Wang Z, Brown JM, Engen PA, Naqib A, Goetz CG, Hall DA, Metman LV, Shaikh M, Forsyth CB, Keshavarzian A (2022) Gut microbial metabolites in Parkinson\u2019s disease: association with lifestyle, disease characteristics, and treatment status. Neurobiol Dis 170:105780. https:\/\/doi.org\/10.1016\/J.NBD.2022.105780","journal-title":"Neurobiol Dis"},{"issue":"1","key":"11014_CR175","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00462-8","volume":"9","author":"K Han","year":"2023","unstructured":"Han K, Kim B, Lee SH, Kim MK (2023) A nationwide cohort study on diabetes severity and risk of Parkinson disease. NPJ Parkinsons Dis 9(1):9. https:\/\/doi.org\/10.1038\/s41531-023-00462-8","journal-title":"NPJ Parkinsons Dis"},{"key":"11014_CR176","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1002\/MDC3.13893","volume":"10","author":"H Tang","year":"2023","unstructured":"Tang H, Lu Y, Okun MS, Donahoo WT, Ramirez-Zamora A, Wang F, Huang Y, Chen WH, Virnig BA, Bian J, Guo J (2023) Meta-analysis of association between newer glucose-lowering drugs and risk of Parkinson\u2019s disease. Mov Disord Clin Pract 10:1659. https:\/\/doi.org\/10.1002\/MDC3.13893","journal-title":"Mov Disord Clin Pract"},{"key":"11014_CR177","doi-asserted-by":"publisher","DOI":"10.3390\/JCM14144947\/S1","volume":"14","author":"GI Tsironikos","year":"2025","unstructured":"Tsironikos GI, Tsolaki V, Zakynthinos GE, Rammou V, Kyprianidou D, Antonogiannis T, Zakynthinos E, Bargiota A (2025) Metformin\u2019s overall effectiveness and combined action with lifestyle interventions in preventing type-2 diabetes mellitus in high-risk metformin-na\u00efve patients: an updated systematic review and meta-analysis of published RCTs. J Clin Med 14:4947. https:\/\/doi.org\/10.3390\/JCM14144947\/S1","journal-title":"J Clin Med"},{"key":"11014_CR178","doi-asserted-by":"publisher","DOI":"10.1002\/MNFR.202400677","volume":"68","author":"RK Gopal","year":"2024","unstructured":"Gopal RK, Ganesh PS, Pathoor NN (2024) Synergistic interplay of diet, gut microbiota, and insulin resistance: unraveling the molecular nexus. Mol Nutr Food Res 68:2400677. https:\/\/doi.org\/10.1002\/MNFR.202400677","journal-title":"Mol Nutr Food Res"},{"key":"11014_CR179","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1111\/ene.15671","volume":"30","author":"S Kleine Bardenhorst","year":"2023","unstructured":"Kleine Bardenhorst S, Cereda E, Severgnini M, Barichella M, Pezzoli G, Keshavarzian A, Desideri A, Pietrucci D, Aho VTE, Scheperjans F, Hildebrand F, Weis S, Egert M, Karch A, Vital M, R\u00fcbsamen N (2023) Gut microbiota dysbiosis in Parkinson disease: a systematic review and pooled analysis. Eur J Neurol 30:3581\u20133594. https:\/\/doi.org\/10.1111\/ene.15671","journal-title":"Eur J Neurol"},{"key":"11014_CR180","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/19490976.2020.1717719","volume":"11","author":"A Adeshirlarijaney","year":"2020","unstructured":"Adeshirlarijaney A, Gewirtz AT (2020) Considering gut microbiota in treatment of type 2 diabetes mellitus. Gut Microbes 11:253\u2013264. https:\/\/doi.org\/10.1080\/19490976.2020.1717719","journal-title":"Gut Microbes"},{"key":"11014_CR181","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2174\/1874609810666170102144233","volume":"10","author":"KN Prasad","year":"2017","unstructured":"Prasad KN (2017) Oxidative stress, pro-inflammatory cytokines, and antioxidants regulate expression levels of microRNAs in Parkinson\u2019s disease. Curr Aging Sci 10:177\u2013184. https:\/\/doi.org\/10.2174\/1874609810666170102144233","journal-title":"Curr Aging Sci"},{"key":"11014_CR182","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.parkreldis.2018.02.022","volume":"50","author":"A Schwiertz","year":"2018","unstructured":"Schwiertz A, Spiegel J, Dillmann U, Grundmann D, B\u00fcrmann J, Fa\u00dfbender K, Sch\u00e4fer KH, Unger MM (2018) Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson\u2019s disease. Parkinsonism Relat Disord 50:104\u2013107. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.02.022","journal-title":"Parkinsonism Relat Disord"},{"key":"11014_CR183","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.diabet.2016.09.004","volume":"43","author":"AJ Cox","year":"2017","unstructured":"Cox AJ, Zhang P, Bowden DW, Devereaux B, Davoren PM, Cripps AW, West NP (2017) Increased intestinal permeability as a risk factor for type 2 diabetes. Diabetes Metab 43:163\u2013166. https:\/\/doi.org\/10.1016\/j.diabet.2016.09.004","journal-title":"Diabetes Metab"},{"key":"11014_CR184","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.2337\/db06-1491","volume":"56","author":"PD Cani","year":"2007","unstructured":"Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delm\u00e9e E, Cousin B, Sulpice T, Chamontin B, Ferri\u00e8res J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56:1761\u20131772. https:\/\/doi.org\/10.2337\/db06-1491","journal-title":"Diabetes"},{"key":"11014_CR185","doi-asserted-by":"publisher","DOI":"10.2139\/SSRN.4212371","author":"E Hogg","year":"2022","unstructured":"Hogg E, Wu T, Bresee C, Wertheimer J, Malatt C, Tan E, Pomeroy H, Nuno M, Wyse R, Tagliati M, Phase A II (2022) Randomized, double-blinded, placebo-controlled trial of liraglutide in Parkinson\u2019s disease. SSRN Electron J. https:\/\/doi.org\/10.2139\/SSRN.4212371","journal-title":"SSRN Electron J"},{"key":"11014_CR186","doi-asserted-by":"publisher","unstructured":"Liraglutide Improves Non-Motor Function and Activities of Daily Living in Patients with Parkinson \u2019 s disease: a Randomized, Double Blind, Placebo-Controlled Trial | Cochrane Library, (n.d.). https:\/\/www.cochranelibrary.com\/central\/doi\/https:\/\/doi.org\/10.1002\/central\/CN-02421849\/full (accessed November 22, 2025).","DOI":"10.1002\/central\/CN-02421849\/full"},{"key":"11014_CR187","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1007\/s00394-020-02282-5","volume":"59","author":"E Birkeland","year":"2020","unstructured":"Birkeland E, Gharagozlian S, Birkeland KI, Valeur J, M\u00e5ge I, Rud I, Aas AM (2020) Prebiotic effect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: a randomised controlled trial. Eur J Nutr 59:3325\u20133338. https:\/\/doi.org\/10.1007\/s00394-020-02282-5","journal-title":"Eur J Nutr"},{"key":"11014_CR188","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcdf.2018.09.001","author":"KN Prasad","year":"2019","unstructured":"Prasad KN, Bondy SC (2019) Dietary fibers and their fermented short-chain fatty acids in prevention of human diseases. Bioact Carbohydr Diet Fibre. https:\/\/doi.org\/10.1016\/j.bcdf.2018.09.001","journal-title":"Bioact Carbohydr Diet Fibre"}],"container-title":["Probiotics and Antimicrobial Proteins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12602-026-11014-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12602-026-11014-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12602-026-11014-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:30:21Z","timestamp":1787729421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12602-026-11014-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":188,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["11014"],"URL":"https:\/\/doi.org\/10.1007\/s12602-026-11014-w","relation":{},"ISSN":["1867-1306","1867-1314"],"issn-type":[{"value":"1867-1306","type":"print"},{"value":"1867-1314","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}